人彌漫大B淋巴瘤細胞OCI-Ly3

簡要描述：青旗（上海）生物技術發展有限公司，總部位于上海浦東新區，依托本地高校資源，逐步發展成為以生物技術為主的研發、生產、培訓為一體的綜合化產業平臺，在標準化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產經營原代細胞、細胞系、ELISA試劑盒、感受態細胞和HPLC檢測等科研產品與服務。我們秉承對用戶負責的態度，以對科研的高度嚴謹，以嚴格的質量控制，為廣大生物醫學科研用戶提供更優質的服務！

更新時間：2021-05-25

廠商性質：生產廠家

瀏覽次數：360

留言詢價聯系我們

詳情介紹

品牌	其他品牌	貨號	BFN607200615
規格	T25培養瓶x1 1.5ml凍存管x2	供貨周期	現貨
主要用途	僅供科研	應用領域	醫療衛生,生物產業

細胞名稱	人彌漫大B淋巴瘤細胞OCI-Ly3
貨物編碼	BFN607200615
產品規格	T25培養瓶x1	1.5ml凍存管x2
細胞數量	1x10^6	1x10^6
保存溫度	27℃	-198℃
運輸方式	常溫保溫運輸	干冰運輸
安全等級	1
用途限制	僅供科研用途 2類

培養體系	DMEM高糖培養基+20%FBS+1%三抗
培養溫度	37℃	二氧化碳濃度	5%
簡介	人彌漫大B淋巴瘤細胞OCI-Ly3細胞于1983年從52歲男性B細胞非霍奇金淋巴瘤骨髓樣本中建立。為常規的藥物篩選模型，懸浮培養，易聚團。引種自DSMZ（ACC-761）
注釋	Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: LL-100 blood cancer cell line panel. Part of: MD Anderson Cell Lines Project. From: Ontario Cancer Institute (OCI); Toronto; Canada. Doubling time: ~24 hours (DSMZ). Omics: Array-based CGH. Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: Genome sequenced. Omics: H3K9ac ChIP-seq epigenome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: SNP array analysis. Omics: Transcriptome analysis. Caution: A cell line, now termed GNE-587170 (CVCL_AT69), was mistakenly distributed by OCI to a number of groups under the designation OCI-Ly-3, the origin of that cell line is now known. Derived from sampling site: Bone marrow.
STR信息	Amelogenin X,Y CSF1PO 10,12 D5S818 12 D7S820 11,12 D13S317 11 D16S539 11,12 TH01 7,9.3 TPOX 8,12 vWA 17
參考文獻	PubMed=3567358 Tweeddale M.E., Lim B., Jamal N., Robinson J., Zalcberg J.R., Lockwood G., Minden M.D., Messner H.A. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood 69:1307-1314(1987) PubMed=8574164; DOI=10.3109/10428199509059672 Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A. p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. Leuk. Lymphoma 19:165-171(1995) PubMed=10676951; DOI=10.1038/35000501 Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson J. Jr., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511(2000) PubMed=11807979; DOI=10.1002/gcc.10025 Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K. Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. Genes Chromosomes Cancer 33:225-234(2002) PubMed=19278952; DOI=10.1182ood-2009-01-202028 Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C., Robetorye R.S., Aguiar R.C.T. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 113:6681-6690(2009) PubMed=22460905; DOI=10.1038/nature11003 Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607(2012) PubMed=23292937; DOI=10.1073/pnas.1205299110 Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C., Naresh K., Evens A., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013) PubMed=23699601; DOI=10.1182ood-2013-02-483727 Morin R.D., Mungall K., Pleasance E.D., Mungall A.J., Goya R., Huff R.D., Scott D.W., Ding J., Roth A., Chiu R., Corbett R.D., Chan F.C., Mendez-Lago M., Trinh D.L., Bolger-Munro M., Taylor G., Hadj Khodabakhshi A., Ben-Neriah S., Pon J., Meissner B., Woolcock B., Farnoud N., Rogic S., Lim E.L., Johnson N.A., Shah S., Jones S., Steidl C., Holt R., Birol I., Moore R., Connors J.M., Gascoyne R.D., Marra M.A. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 122:1256-1265(2013) PubMed=25485619; DOI=10.1038/nbt.3080 Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33:306-312(2015) PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005 Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017) PubMed=30285677; DOI=10.1186/s12885-018-4840-5 Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P. Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines. BMC Cancer 18:940-940(2018) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) PubMed=31160637; DOI=10.1038/s41598-019-44491-x Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G. The LL-100 panel: 100 cell lines for blood cancer studies. Sci. Rep. 9:8218-8218(2019)

驗收細胞注意事項

1、收到人彌漫大B淋巴瘤細胞OCI-Ly3細胞，請查看瓶子是否有破裂，培養基是否漏出，是否渾濁，如有請盡快聯系。

2、收到人彌漫大B淋巴瘤細胞OCI-Ly3細胞，如包裝完好，請在顯微鏡下觀察細胞。,由于運輸過程中的問題，細胞培養瓶中的貼壁細胞有可能從瓶壁中脫落下來，顯微鏡下觀察會出現細胞懸浮的情況，出現此狀態時，請不要打開細胞培養瓶，應立即將培養瓶置于細胞培養箱里靜止 3-5 小時左右，讓細胞先穩定下，再于顯微鏡下觀察，此時多數細胞會重新貼附于瓶壁。如細胞仍不能貼壁，請用臺盼藍染色法鑒定細胞活力，如臺盼藍染色證實細胞活力正常請按懸浮細胞的方法處理。

3、收到人彌漫大B淋巴瘤細胞OCI-Ly3細胞后，請鏡下觀察細胞，用恰當方式處理細胞。若懸浮的細胞較多，請離心收集細胞，接種到一個新的培養瓶中。棄掉原液，使用新鮮配制的培養基，使用進口胎牛血清。剛接到細胞，若細胞不多時血清濃度可以加到 15％去培養。若細胞迏到 80%左右，血清濃度還是在 10％。

4、收到人彌漫大B淋巴瘤細胞OCI-Ly3細胞時如無異常情況，請在顯微鏡下觀察細胞密度，如為貼壁細胞，未超過80%匯合度時，將培養瓶中培養基吸出，留下 5-10ML 培養基繼續培養：超過 80%匯合度時，請按細胞培養條件傳代培養。如為懸浮細胞，吸出培養液，1000 轉/分鐘離心 3 分鐘，吸出上清，管底細胞用新鮮培養基懸浮細胞后移回培養瓶。

5、將培養瓶置于 37℃培養箱中培養，蓋子微微擰松。吸出的培養基可以保存在滅菌過的瓶子里，存放于 4℃冰箱，以備不時之需。

6、24 小時后，細胞形態已恢復并貼滿瓶壁，即可傳代。（貼壁細胞）將培養瓶里的培養基倒去，加 3-5ml（以能覆蓋細胞生長面為準）PBS 或 Hanks’液洗滌后棄去。加 0.5-1ml 0.25%含 EDTA 的胰酶消化，消化時間以具體細胞為準，一般 1-3 分鐘，不超過 5 分鐘。可以放入37℃培養箱消化。輕輕晃動瓶壁，見細胞脫落下來，加入 3-5ml 培養基終止消化。用移液管輕輕吹打瓶壁上的細胞，使之*脫落，然后將溶液吸入離心管內離心，1000rpm/5min。棄上清，視細胞數量決定分瓶數，一般一傳二，如細胞量多可一傳三，有些細胞不易傳得過稀，有些生長較快的細胞則可以多傳幾瓶，以具體細胞和經驗為準。（懸浮細胞）用移液管輕輕吹打瓶壁，直接將溶液吸入離心管離心即可。